GlassScriptPhysician profile
Jaskaran Kaur
NPI 1619545928
$4,049.72
in general payments reported to CMS, 2019-2025
27 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.71 · 2022: $790 · 2023: $725 · 2024: $1,309 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,196.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $703.72 | 2022-2025 | |
| Novo Nordisk INC | $339.58 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $313.88 | 2022-2025 | |
| Daiichi Sankyo INC. | $301.83 | 2024-2025 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $271.05 | 2022 | |
| Alk-Abello, INC | $218.83 | 2024-2025 | Grastek, Odactra, Ragwitek |
| Astrazeneca Pharmaceuticals LP | $200.97 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.54 | 2021-2023 | Jardiance |
| Lilly USA, LLC | $142.27 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Janssen Pharmaceuticals, INC | $139.39 | 2022-2024 | Spravato |
| Amgen INC. | $138.64 | 2023-2024 | Evenity, Prolia, Otezla |
| Hologic Sales and Service, LLC | $137.41 | 2023-2025 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.48 | 2023-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $126.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Viiv Healthcare Company | $126.04 | 2025 | Apretude |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $115.64 | 2025 | Uzedy |
| Organon LLC | $94.16 | 2022-2025 | Nexplanon |
| Pfizer INC. | $72.86 | 2022-2025 | |
| Glaxosmithkline, LLC. | $71.86 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $64.75 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $54.26 | 2022-2023 | Dificid |
| Neurocrine Biosciences, INC. | $35.95 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $31.50 | 2025 | |
| Gilead Sciences, INC. | $20.78 | 2023 | Epclusa |
| Indivior INC. | $20.73 | 2025 | Sublocade |
| Paratek Pharmaceuticals, INC. | $16.37 | 2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaskaran Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.